ClinicalTrials.gg
CompletedNCT06345066Updated Oct 15, 2025

A Study of LY3841136 in Overweight and Obese Participants

A Phase 1 interventional study of Tirzepatide and LY3841136 in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 14 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Enrollment
18th of 22
96 · median 315
Started
2024
with 3 others
Phase 1
9 of 22
4 open now
Registered
5th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 18th largest by enrollment, is one of 4 that started in 2024, is one of 9 in phase 1, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

14 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Safety
  • Tolerability
  • Body weight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are overtly healthy as determined by medical evaluation
  • Have a stable body weight and in range of 27 to 45 kilogram per meter square (kg/m²).
  • Have clinical laboratory test results within normal reference range
  • Have venous access sufficient to allow for blood sampling
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Have type 1 or type 2 diabetes mellitus
  • Have an abnormal 12-lead (ECG)
  • Have a history or presence of psychiatric disorders
  • Have abnormal blood pressure and pulse rate
  • Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    LY3841136 + Tirzepatide

    LY3841136 administered subcutaneously (SC) in combination with tirzepatide given SC.

    Drug: Tirzepatide · Drug: LY3841136

  • Placebo comparator
    Placebo + Tirzepatide

    Placebo administered SC in combination with tirzepatide given SC.

    Drug: Tirzepatide · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to 42 weeks

Secondary outcomes

  1. Percent change from baseline in body weight

    Time frame: Baseline, Week 42

  2. Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3841136

    Time frame: Predose up to 42 weeks

  3. Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of LY3841136

    Time frame: Predose up to 42 weeks

07

Study locations

3 sites
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2025, 17 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
Apr 3, 2024
Primary completionActual
Sep 29, 2025
CompletionActual
Sep 29, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345066
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 3, 2024
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025
Last update
Oct 15, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Start the discussion